Global Surge In Cancer Cases And Its Effect On The Market Driver: Leading Transformation in the Immuno-Oncology Drugs Market in 2025

What combination of drivers is leading to accelerated growth in the immuno-oncology drugs market?
The global ascend in cancer cases is forecasted to propel the growth of the immuno-oncology drugs market. In recent data from January 2022 provided by the American Cancer Society, it is predicted that there will be approximately 1.9 million new cancer detections and 609,360 deaths linked to cancer in the United States, equating to around 1,670 casualties each day. Around the globe, lung, prostate, bowel, and female breast cancer are the four predominantly found types of cancer, responsible for 43% of all newly diagnosed cancer cases. As a result, the surge in worldwide cancer prevalence rates is expected to drive increased demand for immuno-oncology medicines over the forthcoming years.

Get Your Immuno-Oncology Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

What is the projected compound annual growth rate (CAGR) of the immuno-oncology drugs market from 2025 to 2034, and what factors influence it?
The market size for immuno-oncology drugs has seen a swift expansion in the recent past. Predictions suggest an increase from $94.16 billion in 2024 to $106.92 billion in 2025, projecting a compound annual growth rate (CAGR) of 13.6%. Factors contributing to this historical growth include a surge in cancer incidences, robust financial development in emerging markets, escalated spending in healthcare, and a rise in R&D investments in the pharmaceutical sector.

The market for immuno-oncology drugs is anticipated to exhibit robust growth in the forthcoming years, expanding to a value of $153.16 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 9.4%. This predicted growth during the forecast period is likely due to the accelerating investment in immuno-oncology, the heightened emphasis on immunotherapy drugs for cancer treatments, and product advancements. Key trends expected during this period include investing in the creation of personalized oncology drugs for targeted patients, focusing on the production of next-generation biologics, devoting efforts to the formulation of antibody-drug conjugates, injecting funds into Artificial Intelligence solutions, cutting back on R&D costs and shortening development time, exploiting immuno-oncology combination therapies to spur innovation and anchor category leadership, and employing car-t therapies to further boost innovation and fortify category leadership.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

What new trends are reshaping the immuno-oncology drugs market and its opportunities?
Leading firms in the immuno-oncology drugs sector are partnering to innovate and market a ground-breaking checkpoint antibody to augment cancer therapy effectiveness. Such strategic alliances stimulate novelty by promoting an interchange of expertise across various disciplines, thereby accelerating the progress of combined therapies, customised treatments and innovative drug delivery systems. For example, in March 2023, BioNTech SE, originating from Germany, collaborated with OncoC4 Inc from the US, to jointly innovate and market a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody referred to as ONC-392. The aim of this collaboration is to enhance the variety of treatments for cancer across numerous solid tumor types.

What are the major segments of the immuno-oncology drugs market and their role in driving growth?
The immuno-oncology drugs market covered in this report is segmented -

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3455

Which regions are key players in the growth of the immuno-oncology drugs market?
North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the key firms paving the way for growth in the immuno-oncology drugs market?
Major companies operating in the immuno-oncology drugs market include F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

What Is Covered In The Immuno-Oncology Drugs Global Market Report?

• Market Size Forecast: Examine the immuno-oncology drugs market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the immuno-oncology drugs market for a structured understanding.
• Key Players Overview: Analyze major players in the immuno-oncology drugs market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the immuno-oncology drugs market.
• Segment Contributions: Evaluate how different segments drive overall growth in the immuno-oncology drugs market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the immuno-oncology drugs market.
• Industry Challenges: Identify potential risks and obstacles affecting the immuno-oncology drugs market.
• Competitive Landscape: Review strategic developments in the immuno-oncology drugs market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.